Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates. 

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.